DE69526782D1 - Texaphyrin metallkomplexe mit verbesserten funktionellen gruppen - Google Patents

Texaphyrin metallkomplexe mit verbesserten funktionellen gruppen

Info

Publication number: DE69526782D1
Authority: DE; Germany
Prior art keywords: macrocycle; electron; positions; addition; metal complexes
Prior art date: 1994-02-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69526782T

Other languages

English (en)

Other versions

DE69526782T2 (de

Inventor

L Sessler

D Mody

W Hemmi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmacyclics LLC

University of Texas System

Original Assignee

Pharmacyclics LLC

University of Texas System

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-15

Filing date

1995-02-15

Publication date

2002-06-27

1995-02-15 Application filed by Pharmacyclics LLC, University of Texas System filed Critical Pharmacyclics LLC

2002-06-27 Application granted granted Critical

2002-06-27 Publication of DE69526782D1 publication Critical patent/DE69526782D1/de

2003-03-06 Publication of DE69526782T2 publication Critical patent/DE69526782T2/de

2015-02-16 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000002184 metal Substances 0.000 title abstract 2
150000002678 macrocyclic compounds Chemical class 0.000 abstract 4
125000006575 electron-withdrawing group Chemical group 0.000 abstract 2
230000007062 hydrolysis Effects 0.000 abstract 2
238000006460 hydrolysis reaction Methods 0.000 abstract 2
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
150000004696 coordination complex Chemical class 0.000 abstract 1
238000007324 demetalation reaction Methods 0.000 abstract 1
238000007306 functionalization reaction Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
LGAILEFNHXWAJP-BMEPFDOTSA-N macrocycle Chemical group N([C@H]1[C@@H](C)CC)C(=O)C(N=2)=CSC=2CNC(=O)C(=C(O2)C)N=C2[C@H]([C@@H](C)CC)NC(=O)C2=CSC1=N2 LGAILEFNHXWAJP-BMEPFDOTSA-N 0.000 abstract 1
230000006641 stabilisation Effects 0.000 abstract 1
238000011105 stabilization Methods 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Radiology & Medical Imaging (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Laminated Bodies (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Reinforced Plastic Materials (AREA)
Saccharide Compounds (AREA)
Surface Treatment Of Glass Fibres Or Filaments (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

DE69526782T 1994-02-15 1995-02-15 Texaphyrin metallkomplexe mit verbesserten funktionellen gruppen Expired - Fee Related DE69526782T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/196,964 US5599923A (en)	1989-03-06	1994-02-15	Texaphyrin metal complexes having improved functionalization
PCT/US1995/001996 WO1995021845A1 (en)	1994-02-15	1995-02-15	Texaphyrin metal complexes having improved functionalization

Publications (2)

Publication Number	Publication Date
DE69526782D1 true DE69526782D1 (de)	2002-06-27
DE69526782T2 DE69526782T2 (de)	2003-03-06

Family

ID=22727479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69526782T Expired - Fee Related DE69526782T2 (de)	1994-02-15	1995-02-15	Texaphyrin metallkomplexe mit verbesserten funktionellen gruppen

Country Status (14)

Country	Link
US (2)	US5599923A (de)
EP (1)	EP0745085B1 (de)
JP (1)	JPH10500659A (de)
KR (1)	KR970701193A (de)
AT (1)	ATE217874T1 (de)
AU (1)	AU688008B2 (de)
CA (1)	CA2182960A1 (de)
DE (1)	DE69526782T2 (de)
DK (1)	DK0745085T3 (de)
ES (1)	ES2173951T3 (de)
NO (1)	NO308473B1 (de)
NZ (1)	NZ282185A (de)
PT (1)	PT745085E (de)
WO (1)	WO1995021845A1 (de)

Families Citing this family (609)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5457183A (en) *	1989-03-06	1995-10-10	Board Of Regents, The University Of Texas System	Hydroxylated texaphyrins
US5252720A (en) *	1989-03-06	1993-10-12	Board Of Regents, The University Of Texas System	Metal complexes of water soluble texaphyrins
US5567687A (en) *	1989-03-06	1996-10-22	University Of Texas	Texaphyrins and uses thereof
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
US5607924A (en) *	1992-01-21	1997-03-04	Pharmacyclics, Inc.	DNA photocleavage using texaphyrins
US5565552A (en) *	1992-01-21	1996-10-15	Pharmacyclics, Inc.	Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5888997A (en) *	1994-04-14	1999-03-30	Pharmacyclics, Inc.	Radiation sensitization using texaphyrins
US5595726A (en) *	1992-01-21	1997-01-21	Pharmacyclics, Inc.	Chromophore probe for detection of nucleic acid
US5523389A (en) *	1992-09-29	1996-06-04	Isis Pharmaceuticals, Inc.	Inhibitors of human immunodeficiency virus
US5798491A (en) *	1993-06-09	1998-08-25	Board Of Regents, The University Of Texas System	Multi-mechanistic chemical cleavage using certain metal complexes
ATE247128T1 (de)	1993-09-03	2003-08-15	Isis Pharmaceuticals Inc	Aminoderivatisierte nukleoside und oligonukleoside
US5969111A (en) *	1994-04-14	1999-10-19	Board Of Regents, The University Of Texas System	Texaphyrins substituted with imidazole are provided
US5633354A (en) *	1994-09-21	1997-05-27	Pharmacyclics, Inc.	Phosphoramidite derivatives of texaphyrins
US5837866A (en) *	1994-09-21	1998-11-17	Board Of Regents, The University Of Texas	Phosphoramidite derivatives of macrocycles
US6210356B1 (en) *	1998-08-05	2001-04-03	Ekos Corporation	Ultrasound assembly for use with a catheter
US6176842B1 (en) *	1995-03-08	2001-01-23	Ekos Corporation	Ultrasound assembly for use with light activated drugs
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
US5714328A (en) *	1995-06-07	1998-02-03	Board Of Regents, The University Of Texas System	RNA photocleavage using texaphyrins
RU2106146C1 (ru)	1995-07-17	1998-03-10	Институт элементоорганических соединений РАН	Средство для подавления опухолевого роста
US5776925A (en) *	1996-01-25	1998-07-07	Pharmacyclics, Inc.	Methods for cancer chemosensitization
WO1997035617A1 (en) *	1996-03-26	1997-10-02	Pharmacyclics, Inc.	Use of a texaphyrin in photodynamic therapy of pigment-related lesions
DE69727833T2 (de) *	1996-06-04	2005-01-13	Board of Regents, The University of Texas System, Austin	Membraneinbau von texaphyrinen
US6375930B2 (en)	1996-06-04	2002-04-23	Board Of Regents, The University Of Texas System	Membrane incorporation of texaphyrins
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US20050119470A1 (en) *	1996-06-06	2005-06-02	Muthiah Manoharan	Conjugated oligomeric compounds and their use in gene modulation
US5898031A (en) *	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US20040203024A1 (en) *	1996-06-06	2004-10-14	Baker Brenda F.	Modified oligonucleotides for use in RNA interference
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US20040147022A1 (en) *	1996-06-06	2004-07-29	Baker Brenda F.	2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20040266706A1 (en) *	2002-11-05	2004-12-30	Muthiah Manoharan	Cross-linked oligomeric compounds and their use in gene modulation
US20040171031A1 (en) *	1996-06-06	2004-09-02	Baker Brenda F.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7812149B2 (en) *	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
WO2005121368A1 (en) *	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Chimeric gapped oligomeric compositions
US20050053976A1 (en) *	1996-06-06	2005-03-10	Baker Brenda F.	Chimeric oligomeric compounds and their use in gene modulation
US6022959A (en) *	1996-08-20	2000-02-08	Pharmacyclics, Inc.	Nucleic acids internally-derivatized with a texaphyrin metal complex and uses thereof
US6331286B1 (en)	1998-12-21	2001-12-18	Photogen, Inc.	Methods for high energy phototherapeutics
US6270749B1 (en) *	1996-12-11	2001-08-07	Pharmacyclics, Inc.	Use of Texaphyrin in ocular diagnosis and therapy
EP1091742A4 (de)	1997-02-14	2007-05-30	Miravant Pharm Inc	Indium photosensibilisatoren zur pdt
JPH10279502A (ja) *	1997-03-31	1998-10-20	Katsuro Tachibana	光感受性物質の励起方法
US6716625B1 (en)	1997-04-16	2004-04-06	Claude Selitrennikoff	Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
WO1998047539A1 (en) *	1997-04-22	1998-10-29	Nycomed Imaging As	Nmr image compounds
US6582392B1 (en) *	1998-05-01	2003-06-24	Ekos Corporation	Ultrasound assembly for use with a catheter
US6676626B1 (en) *	1998-05-01	2004-01-13	Ekos Corporation	Ultrasound assembly with increased efficacy
WO1999001579A1 (en)	1997-07-01	1999-01-14	Isis Pharmaceuticals, Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US5886173A (en) *	1997-07-30	1999-03-23	Pharmacyclics, Inc.	Metallation of macrocycles with 2,4-dicarbonyl-metal complexes
US6022526A (en) *	1997-07-30	2000-02-08	Pharmacyclics, Inc.	Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
US6495118B1 (en)	1997-09-26	2002-12-17	Schering Aktiengesellschaft	Lipophilic metal complexes for necrosis and infarction imaging
US8974363B2 (en) *	1997-12-11	2015-03-10	Provectus Pharmatech, Inc.	Topical medicaments and methods for photodynamic treatment of disease
US7321828B2 (en) *	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
US20040186071A1 (en) *	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
EP1080103A4 (de) *	1998-05-21	2003-07-02	Isis Pharmaceuticals Inc	Zubereitungen und verfahren zur nicht-parenteralen verabreichung von oligonukleotiden
US6841539B1 (en) *	1998-05-21	2005-01-11	Isis Pharmaceuticals, Inc.	Compositions and methods for topical delivery of oligonucleotides
DE19831217A1 (de) *	1998-07-03	2000-01-05	Schering Ag	Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US20090117199A1 (en) *	1998-08-06	2009-05-07	Scott Timothy C	Method of treatment of cancer
US8557298B2 (en) *	1998-08-06	2013-10-15	Provectus Pharmatech, Inc.	Medicaments for chemotherapeutic treatment of disease
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US20020001567A1 (en) *	1998-12-21	2002-01-03	Photogen, Inc.	Intracorporeal medicaments for high energy phototherapeutic treatment of disease
US8470296B2 (en) *	1998-12-21	2013-06-25	Provectus Pharmatech, Inc.	Intracorporeal medicaments for high energy phototherapeutic treatment of disease
US7384623B1 (en)	1998-12-21	2008-06-10	Provectus Pharmatech, Inc.	High energy phototherapeutic agents
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6821738B2 (en) *	1999-01-20	2004-11-23	The Board Of Regents For Oklahoma State University	Broad spectrum bio-detection of nerve agents, organophosphates, and other chemical warfare agents
US6127124A (en)	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US6838292B1 (en)	1999-04-19	2005-01-04	Alion Science And Technology Corporation	Detection of biological warfare agents
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
EP1206288B1 (de) *	1999-08-02	2007-01-10	The Regents Of The University Of Michigan	Zielgerichtete fiberlose radiative effektoren
WO2001032210A2 (en) *	1999-10-29	2001-05-10	Pharmacyclics, Inc.	Compositions for treating atheroma and neoplastic tissue
US7579338B2 (en) *	1999-10-29	2009-08-25	Pharmacyclics, Inc.	Methods and compositions for treating atheroma, tumors and other neoplastic tissues
US7897140B2 (en) *	1999-12-23	2011-03-01	Health Research, Inc.	Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20030176385A1 (en) *	2000-02-15	2003-09-18	Jingfang Ju	Antisense modulation of protein expression
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US8568766B2 (en) *	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
US6638924B2 (en)	2000-08-30	2003-10-28	Pharmacyclics, Inc.	Metallotexaphyrin derivatives
US7449454B2 (en) *	2000-08-30	2008-11-11	Pharmacyclics, Inc.	Metallotexaphyrin derivatives
US7112671B2 (en) *	2000-08-30	2006-09-26	Pharmacyclics, Inc.	Non-symmetric tripyrranes in the synthesis of novel macrocycles
AU2001296846B2 (en)	2000-10-12	2007-07-05	University Of Rochester	Compositions that inhibit proliferation of cancer cells
AU2002236458A1 (en) *	2000-11-17	2002-05-27	Pharmacyclics, Inc.	Texaphyrin coordination compounds and uses thereof
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
MXPA03011985A (es)	2001-06-20	2004-03-26	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumores.
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) *	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
CA2451643C (en)	2001-06-21	2012-11-13	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
ES2390531T3 (es)	2001-09-18	2012-11-13	Genentech, Inc.	Composiciones y procedimientos para el diagnósitco y tratamiento de tumor
NZ585001A (en)	2001-10-09	2011-08-26	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expression
KR100437547B1 (ko) *	2001-10-09	2004-06-30	김환규	희토류 이온을 포함하는 착염형 텍사피린 덴드리머 화합물및 그 제조방법
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
AU2002359576A1 (en)	2001-12-03	2003-06-17	Ekos Corporation	Catheter with multiple ultrasound radiating members
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
EP2067472A1 (de)	2002-01-02	2009-06-10	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US6984734B2 (en)	2002-02-26	2006-01-10	Board Of Regents, The University Of Texas System	Cyclo[n]pyrroles and methods thereto
US6723750B2 (en)	2002-03-15	2004-04-20	Allergan, Inc.	Photodynamic therapy for pre-melanomas
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
US8226629B1 (en)	2002-04-01	2012-07-24	Ekos Corporation	Ultrasonic catheter power control
NZ535925A (en)	2002-04-16	2008-06-30	Genentech Inc	An isolated antibody that binds to a particular polypeptide
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
JP4529344B2 (ja) *	2002-06-03	2010-08-25	ニプロ株式会社	腫瘍組織の酸素濃度を上昇させるためのポルフィリン酸素輸液製剤
US20040092470A1 (en) *	2002-06-18	2004-05-13	Leonard Sherry A.	Dry powder oligonucleotide formualtion, preparation and its uses
CA2490692A1 (en)	2002-06-27	2004-01-08	Health Research, Inc.	Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
AU2003249742A1 (en) *	2002-07-02	2004-01-23	Health Research, Inc.	Efficient synthesis of pyropheophorbide a and its derivatives
US20040019000A1 (en) *	2002-07-19	2004-01-29	Muthiah Manoharan	Polyalkyleneamine-containing oligomers
CA2495478A1 (en)	2002-08-05	2004-02-12	University Of Rochester	Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US6878805B2 (en) *	2002-08-16	2005-04-12	Isis Pharmaceuticals, Inc.	Peptide-conjugated oligomeric compounds
JP2005538186A (ja)	2002-09-13	2005-12-15	レプリコールインコーポレーティッド	非配列相補性の抗ウイルス性オリゴヌクレオチド
EP1549767A4 (de)	2002-09-26	2006-06-07	Amgen Inc	Modulation der expression von forkhead-box o1a
US6921371B2 (en) *	2002-10-14	2005-07-26	Ekos Corporation	Ultrasound radiating members for catheter
JP2006515318A (ja) *	2002-10-29	2006-05-25	ファルマシア・コーポレーション	特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
EP1560839A4 (de)	2002-11-05	2008-04-23	Isis Pharmaceuticals Inc	Chimäre oligomere verbindungen und derenverwendung in der genmodulation
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP1578765A4 (de) *	2002-11-05	2008-04-23	Isis Pharmaceuticals Inc	Oligomere verbindungen,die zuckerersatzstoffe enthalten, und zusammensetzung zur verwendung in dergenmodulation
US9150606B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
DK2336318T3 (da)	2002-11-13	2013-07-15	Genzyme Corp	Antisense-modulering af apolipoprotein b-ekspression
EP1569695B1 (de)	2002-11-13	2013-05-15	Genzyme Corporation	Antisense-modulation von apolipoprotein-b-expression
WO2004046330A2 (en) *	2002-11-15	2004-06-03	Morphotek, Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
JP4915980B2 (ja)	2002-11-15	2012-04-11	エムユーエスシーファウンデーションフォーリサーチデベロップメント	補体レセプター２標的化補体調節因子
US7557092B2 (en)	2002-11-21	2009-07-07	University Of Utah Research Foundation	Purinergic modulation of smell
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
CA2515484C (en)	2003-02-11	2011-09-20	Antisense Therapeutics Ltd	Modulation of insulin like growth factor i receptor expression
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
WO2004108081A2 (en) *	2003-06-02	2004-12-16	Isis Pharmaceuticals, Inc.	Oligonucleotide synthesis with alternative solvents
WO2005002507A2 (en)	2003-06-03	2005-01-13	Isis Pharmaceuticals, Inc.	Modulation of survivin expression
DK3604537T3 (da)	2003-06-13	2022-02-28	Alnylam Europe Ag	Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
WO2005044976A2 (en) *	2003-06-20	2005-05-19	Isis Pharmaceuticals, Inc.	Oligomeric compounds for use in gene modulation
WO2004113496A2 (en) *	2003-06-20	2004-12-29	Isis Pharmaceuticals, Inc.	Double stranded compositions comprising a 3’-endo modified strand for use in gene modulation
US7057100B2 (en) *	2003-06-26	2006-06-06	The J.C. Robinson Seed Co.	Inbred corn line W23129
US7025840B1 (en)	2003-07-15	2006-04-11	Lockheed Martin Corporation	Explosive/energetic fullerenes
CA2533701A1 (en)	2003-07-31	2005-02-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070123480A1 (en) *	2003-09-11	2007-05-31	Replicor Inc.	Oligonucleotides targeting prion diseases
AU2004274021B2 (en)	2003-09-18	2009-08-13	Isis Pharmaceuticals, Inc.	4'-thionucleosides and oligomeric compounds
EP2182063A3 (de)	2003-09-18	2012-07-18	Isis Pharmaceuticals, Inc.	Modulierung von EIF4E-Expression
EP1678194B1 (de)	2003-10-10	2013-06-26	Alchemia Oncology Pty Limited	Modulation der synthese und des abbaus von hyaluronan bei der behandlung von krankheiten
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
JP4901478B2 (ja)	2003-11-17	2012-03-21	ジェネンテック，インコーポレイテッド	造血系起源の腫瘍の治療のための組成物と方法
EP1711606A2 (de)	2004-01-20	2006-10-18	Isis Pharmaceuticals, Inc.	Modulation der expression des glucocorticoidrezeptors
US7468431B2 (en) *	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US8569474B2 (en) *	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP2700720A3 (de)	2004-03-15	2015-01-28	Isis Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
WO2005097817A2 (en)	2004-04-05	2005-10-20	Alnylam Pharmaceuticals, Inc.	Process and reagents for oligonucleotide synthesis and purification
US20050244869A1 (en) *	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US20050260755A1 (en) *	2004-04-06	2005-11-24	Isis Pharmaceuticals, Inc.	Sequential delivery of oligomeric compounds
US20050260652A1 (en) *	2004-04-15	2005-11-24	The General Hospital Corporation	Compositions and methods that modulate RNA interference
US7674778B2 (en)	2004-04-30	2010-03-09	Alnylam Pharmaceuticals	Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
JP2008513048A (ja) *	2004-05-20	2008-05-01	ファーマサイクリックス，インコーポレイテッド	アテローム性動脈硬化プラークの可視化を増強する方法
DK1773872T3 (en)	2004-05-21	2017-05-08	Uab Res Found	VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
US8394947B2 (en) *	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
AU2005252662B2 (en) *	2004-06-03	2011-08-18	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
WO2006023880A2 (en) *	2004-08-23	2006-03-02	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en) *	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
ES2729826T3 (es)	2004-09-23	2019-11-06	Arc Medical Devices Inc	Composiciones farmacéuticas y métodos relacionados para inhibir adherencias fibrosas o enfermedad inflamatoria usando fucanos con bajo contenido de sulfato
US20060099712A1 (en) *	2004-11-08	2006-05-11	Eastman Kodak Company	Correlation of anti-cancer activity of dyes with redox potentials
JP2006224318A (ja) *	2005-02-15	2006-08-31	Brother Ind Ltd	インクジェット記録装置
CN101175769A (zh)	2005-03-10	2008-05-07	健泰科生物技术公司	用于调控血管完整性的方法和组合物
US7476733B2 (en) *	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US20100028439A1 (en) *	2005-05-23	2010-02-04	Elan Pharma International Limited	Nanoparticulate stabilized anti-hypertensive compositions
WO2007008300A2 (en)	2005-05-31	2007-01-18	ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE	Triblock copolymers for cytoplasmic delivery of gene-based drugs
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
US20070072838A1 (en)	2005-09-26	2007-03-29	Pharmacyclics, Inc.	High-purity texaphyrin metal complexes
US20070078119A1 (en) *	2005-09-30	2007-04-05	Pharmacyclics, Inc.	Storage system for texaphyrin pharmaceutical formulations
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP1934331A4 (de)	2005-10-14	2009-01-21	Musc Found For Res Dev	Pax2 als ziel für die induktion von defb1-vermittelter tumorimmunität und krebstherapie
AU2006305886C1 (en)	2005-10-28	2011-03-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of huntingtin gene
US20100069461A1 (en)	2005-11-09	2010-03-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
JP2009516710A (ja)	2005-11-21	2009-04-23	アイシスファーマシューティカルズ，インコーポレーテッド	ｅＩＦ４Ｅ−ＢＰ２の発現のモジュレート
KR101547579B1 (ko)	2006-03-31	2015-08-27	알닐람 파마슈티칼스 인코포레이티드	Ｅｇ5 유전자의 발현을 억제하는 이본쇄 리보핵산
KR20120018232A (ko) *	2006-03-31	2012-03-02	에모리 유니버시티	광 활성화 항바이러스 물질 및 바이러스 감염된 환경을 탈오염화시키기 위한 장치 및 방법
CA2651031A1 (en) *	2006-05-03	2007-11-08	Baltic Technology Development, Ltd.	Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
CN101489566B (zh)	2006-05-19	2012-04-18	阿尔尼拉姆医药品有限公司	Aha基因的RNAi调控及其治疗性应用
CA2653451C (en)	2006-05-22	2015-12-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of ikk-b gene
WO2007137301A2 (en) *	2006-05-23	2007-11-29	Isis Pharmaceuticals, Inc.	Modulation of chrebp expression
US9506056B2 (en) *	2006-06-08	2016-11-29	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
US20090280188A1 (en) *	2006-06-23	2009-11-12	Northwestern University	Asymmetric functionalizated nanoparticles and methods of use
US8198253B2 (en)	2006-07-19	2012-06-12	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to HBXIP
US8133474B2 (en) *	2006-09-15	2012-03-13	Massachusetts Institute Of Technology	Sensors for fluorescence and magnetic resonance imaging
WO2008136852A2 (en)	2006-11-01	2008-11-13	University Of Rochester	Methods and compositions related to the structure and function of apobec3g
CA2672297A1 (en) *	2006-12-11	2008-06-19	University Of Utah Research Foundation	Compositions and methods for treating pathologic angiogenesis and vascular permeability
US10182833B2 (en)	2007-01-08	2019-01-22	Ekos Corporation	Power parameters for ultrasonic catheter
EP2121987B1 (de) *	2007-02-09	2012-06-13	Northwestern University	Partikel zur erkennung intrazellulärer ziele
JP5350360B2 (ja)	2007-03-29	2013-11-27	アルナイラムファーマシューティカルズ，インコーポレイテッド	エボラ由来の遺伝子の発現を阻害するための組成物および方法
EP2494932B1 (de)	2007-06-22	2020-05-20	Ekos Corporation	Vorrichtung zur Behandlung von intrakranialen Blutungen
WO2009006075A2 (en) *	2007-06-29	2009-01-08	Board Of Regents, The University Of Texas System	Functionalized expanded porphyrins
DK2682400T5 (da) *	2007-08-28	2017-11-27	Uab Research Foundation	Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse
JP2010537638A (ja)	2007-08-28	2010-12-09	ユーエービーリサーチファウンデーション	合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
WO2009039466A1 (en)	2007-09-20	2009-03-26	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
WO2009039442A1 (en) *	2007-09-21	2009-03-26	California Institute Of Technology	Nfia in glial fate determination, glioma therapy and astrocytoma treatment
CA2700953A1 (en)	2007-10-02	2009-04-09	Amgen Inc.	Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
BRPI0819193A2 (pt) *	2007-11-05	2017-05-23	Baltic Tech Dev Ltd	uso de oligonucleotídeos com bases modificadas na hibridização de ácidos nucleicos.
EP2222851B1 (de)	2007-11-20	2017-06-28	Ionis Pharmaceuticals, Inc.	Modulation der cd40-expression
JP5530933B2 (ja)	2007-12-10	2014-06-25	アルナイラムファーマシューティカルズ，インコーポレイテッド	第ｖｉｉ因子遺伝子発現阻害のための組成物及び方法
US20090187137A1 (en) *	2007-12-14	2009-07-23	Kim Volz	Ultrasound pulse shaping
JP2011518117A (ja)	2008-03-05	2011-06-23	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｅｇ５およびＶＥＧＦ遺伝子の発現を阻害するための組成物および方法
EP2105145A1 (de) *	2008-03-27	2009-09-30	ETH Zürich	Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
EP2274423A2 (de) *	2008-04-04	2011-01-19	Isis Pharmaceuticals, Inc.	Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
CA2721183C (en)	2008-04-11	2019-07-16	Alnylam Pharmaceuticals, Inc.	Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US8324366B2 (en)	2008-04-29	2012-12-04	Alnylam Pharmaceuticals, Inc.	Compositions and methods for delivering RNAI using lipoproteins
WO2010017509A1 (en) *	2008-08-07	2010-02-11	Isis Pharmaceuticals, Inc.	Modulation of transthyretin expression for the treatment of cns related disorders
EP3081648A1 (de)	2008-08-25	2016-10-19	Excaliard Pharmaceuticals, Inc.	Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
WO2010028054A1 (en)	2008-09-02	2010-03-11	Alnylam Europe Ag.	Compositions and methods for inhibiting expression of mutant egfr gene
JP2012513953A (ja)	2008-09-23	2012-06-21	アルニラムファーマスーティカルズインコーポレイテッド	付加環化を用いたモノマーおよびオリゴヌクレオチドの化学修飾
EP2334793B1 (de)	2008-09-25	2016-04-06	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
EA029762B1 (ru)	2008-10-20	2018-05-31	Элнилэм Фармасьютикалз, Инк.	Композиции и способы для ингибирования экспрессии транстиретина
EP2447274B1 (de)	2008-10-24	2017-10-04	Ionis Pharmaceuticals, Inc.	Oligomerverbindungen und Verfahren
KR20220150995A (ko)	2008-11-10	2022-11-11	알닐람 파마슈티칼스 인코포레이티드	치료제 운반용 신규 지질 및 조성물
DK2365803T3 (en) *	2008-11-24	2018-01-22	Univ Northwestern	POLYVALENT RNA NANOPARTICLE COMPOSITIONS
US8802074B2 (en) *	2008-11-26	2014-08-12	Board Of Regents, The University Of Texas System	Polymers functionalized with ion-specific recognition elements
ES2637063T3 (es)	2008-12-04	2017-10-10	Curna, Inc.	Tratamiento de enfermedades relacionadas con genes supresores de tumor mediante inhibición del transcrito antisentido natural al gen
WO2010065792A2 (en)	2008-12-04	2010-06-10	Curna, Inc.	Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
MX366774B (es)	2008-12-04	2019-07-24	Curna Inc	Uso de oligonucleótidos antisentido en la inhibición de transcrito antisentido natural para sirtuina 1.
WO2010068816A1 (en)	2008-12-10	2010-06-17	Alnylam Pharmaceuticals, Inc.	Gnaq targeted dsrna compositions and methods for inhibiting expression
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
US20100184844A1 (en) *	2009-01-08	2010-07-22	Northwestern University	Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
EP2393825A2 (de)	2009-02-06	2011-12-14	Isis Pharmaceuticals, Inc.	Oligomere verbindungen und verfahren
PL2396038T3 (pl)	2009-02-12	2016-05-31	Curna Inc	Leczenie chorób związanych z neurotropowym czynnikiem pochodzenia mózgowego (bdnf) poprzez zahamowanie naturalnego antysensownego transkryptu bdnf
US20110319476A1 (en)	2009-02-12	2011-12-29	Opko Curna, Llc	Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
US8975389B2 (en)	2009-03-02	2015-03-10	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
EP2403946A4 (de)	2009-03-04	2012-11-14		Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
JP6032724B2 (ja)	2009-03-12	2016-11-30	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	脂質製剤組成物およびＥｇ５遺伝子とＶＥＧＦ遺伝子の発現を阻害する方法
US9464287B2 (en)	2009-03-16	2016-10-11	Curna, Inc.	Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
CA2755404C (en)	2009-03-17	2020-03-24	Joseph Collard	Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
EP3248618A1 (de)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
US8318690B2 (en)	2009-05-01	2012-11-27	Curna, Inc.	Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG
CN106237345A (zh)	2009-05-06	2016-12-21	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
ES2609655T3 (es)	2009-05-06	2017-04-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
JP5922017B2 (ja)	2009-05-18	2016-05-24	クルナ・インコーポレーテッド	リプログラミング因子に対する天然アンチセンス転写物の抑制によるリプログラミング因子関連疾患の治療
WO2010135695A2 (en)	2009-05-22	2010-11-25	Curna, Inc.	TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
EP2435571B1 (de)	2009-05-28	2016-12-14	CuRNA, Inc.	Behandlung von durch antivirale gene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein antivirales gen
CN104873464B (zh)	2009-06-10	2018-06-22	阿布特斯生物制药公司	改进的脂质制剂
KR101801404B1 (ko)	2009-06-16	2017-12-20	큐알엔에이, 인크.	콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
ES2629339T3 (es)	2009-06-16	2017-08-08	Curna, Inc.	Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
NZ624712A (en)	2009-06-17	2015-10-30	Isis Pharmaceuticals Inc	Compositions and methods for modulation of smn2 splicing in a subject
CA2765889A1 (en)	2009-06-24	2010-12-29	Opko Curna, Llc	Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
KR101807324B1 (ko)	2009-06-26	2017-12-08	큐알엔에이, 인크.	다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
CA2769665A1 (en)	2009-08-05	2011-02-10	Opko Curna, Llc	Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
AP2015008874A0 (en)	2009-08-14	2015-11-30	Alnylam Pharmaceuticals Inc	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
KR101892760B1 (ko)	2009-08-25	2018-08-28	큐알엔에이, 인크.	ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
DK2473522T3 (en)	2009-09-02	2016-11-28	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
RU2539772C2 (ru)	2009-10-22	2015-01-27	Дженентек, Инк.	Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
AU2010313154B2 (en)	2009-10-30	2016-05-12	Northwestern University	Templated nanoconjugates
PE20121584A1 (es)	2009-11-30	2012-11-29	Genentech Inc	Composiciones y metodos para el diagnostico y el tratamiento de tumores
CA3044884A1 (en)	2009-12-07	2011-06-16	Arbutus Biopharma Corporation	Compositions for nucleic acid delivery
ES2661813T3 (es)	2009-12-16	2018-04-04	Curna, Inc.	Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1
US20130017223A1 (en)	2009-12-18	2013-01-17	The University Of British Columbia	Methods and compositions for delivery of nucleic acids
WO2011079261A2 (en)	2009-12-23	2011-06-30	Curna, Inc.	Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
EP2515947B1 (de)	2009-12-23	2021-10-06	CuRNA, Inc.	Behandlung von durch das uncoupling protein 2 (ucp2) bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts für ucp2
RU2615450C2 (ru)	2009-12-29	2017-04-04	Курна, Инк.	Лечение заболеваний, связанных с ядерным респираторным фактором 1(nrf1), путем ингибирования природного антисмыслового транскрипта к nrf1
JP5982288B2 (ja)	2009-12-29	2016-08-31	カッパーアールエヌエー，インコーポレイテッド	腫瘍タンパク質６３（ｐ６３）に対する天然アンチセンス転写物の阻害による腫瘍タンパク質６３関連疾患の治療
DK2521784T3 (en)	2010-01-04	2018-03-12	Curna Inc	TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
JP5963680B2 (ja)	2010-01-06	2016-08-03	カッパーアールエヌエー，インコーポレイテッド	膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
WO2011085347A2 (en)	2010-01-11	2011-07-14	Opko Curna, Llc	Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
ES2671877T3 (es)	2010-01-25	2018-06-11	Curna, Inc.	Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
WO2011094580A2 (en)	2010-01-28	2011-08-04	Alnylam Pharmaceuticals, Inc.	Chelated copper for use in the preparation of conjugated oligonucleotides
US9198972B2 (en)	2010-01-28	2015-12-01	Alnylam Pharmaceuticals, Inc.	Monomers and oligonucleotides comprising cycloaddition adduct(s)
CA2824843A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
CN102844435B (zh)	2010-02-22	2017-05-10	库尔纳公司	通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
KR20130004579A (ko)	2010-02-23	2013-01-11	제넨테크, 인크.	종양의 진단 및 치료를 위한 조성물 및 방법
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
EP2544703A4 (de)	2010-03-12	2013-09-18	Brigham & Womens Hospital	Verfahren zur behandlung von gefässentzündungserkrankungen
AU2011235276B2 (en)	2010-03-29	2015-09-03	Alnylam Pharmaceuticals, Inc.	SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
WO2011123621A2 (en)	2010-04-01	2011-10-06	Alnylam Pharmaceuticals Inc.	2' and 5' modified monomers and oligonucleotides
EP2556160A4 (de)	2010-04-09	2013-08-21	Curna Inc	Behandlung von erkrankungen im zusammenhang mit dem fibroblastenwachstumsfaktor 21 (fgf21) mittels hemmung des natürlichen antisense-transkripts gegen fgf21
US10913767B2 (en)	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133868A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Conformationally restricted dinucleotide monomers and oligonucleotides
US9725479B2 (en)	2010-04-22	2017-08-08	Ionis Pharmaceuticals, Inc.	5′-end derivatives
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
EP2625186B1 (de)	2010-04-28	2016-07-27	Ionis Pharmaceuticals, Inc.	5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
CN103154014B (zh)	2010-04-28	2015-03-25	Isis制药公司	修饰核苷、其类似物以及由它们制备的寡聚化合物
ES2625689T3 (es)	2010-04-29	2017-07-20	Ionis Pharmaceuticals, Inc.	Modulación de la expresión de transtiretina
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
CN107090045A (zh)	2010-05-03	2017-08-25	霍夫曼-拉罗奇有限公司	用于肿瘤诊断和治疗的组合物和方法
WO2011139387A1 (en)	2010-05-03	2011-11-10	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI586356B (zh)	2010-05-14	2017-06-11	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
KR20180053419A (ko)	2010-05-26	2018-05-21	큐알엔에이, 인크.	무조(無調)의 동소체 1 (atoh1)에 대한 자연 안티센스 전사체의 저해에 의한 atoh1 관련된 질환의 치료
EP2576579B1 (de)	2010-06-02	2018-08-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von leberfibrose
US9638632B2 (en)	2010-06-11	2017-05-02	Vanderbilt University	Multiplexed interferometric detection system and method
US20130236968A1 (en)	2010-06-21	2013-09-12	Alnylam Pharmaceuticals, Inc.	Multifunctional copolymers for nucleic acid delivery
WO2012009402A2 (en)	2010-07-14	2012-01-19	Opko Curna Llc	Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
WO2012016188A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
WO2012016184A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
SG188666A1 (en)	2010-09-30	2013-05-31	Agency Science Tech & Res	Methods and reagents for detection and treatment of esophageal metaplasia
AU2011312205B2 (en)	2010-10-05	2015-08-13	Curis, Inc.	Mutant smoothened and methods of using the same
CA2813901C (en)	2010-10-06	2019-11-12	Curna, Inc.	Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
US20140031250A1 (en)	2010-10-07	2014-01-30	David Tsai Ting	Biomarkers of Cancer
EP2630241B1 (de)	2010-10-22	2018-10-17	CuRNA, Inc.	Behandlung von alpha-l-iduronidase (idua)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen idua
ES2677070T3 (es)	2010-10-27	2018-07-27	Curna, Inc.	Tratamiento de enfermedades relacionadas con el regulador del desarrollo 1 asociado a interferón (ifrd1) mediante inhibición del transcrito antisentido natural al gen ifrd1
CN110123830A (zh)	2010-11-09	2019-08-16	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
EP2638163B1 (de)	2010-11-12	2017-05-17	The General Hospital Corporation	Polycomb-assoziierte nicht-kodierende rnas
ES2657590T3 (es)	2010-11-23	2018-03-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
WO2012078967A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (epo) production
EP2648763A4 (de)	2010-12-10	2014-05-14	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
WO2012099755A1 (en)	2011-01-11	2012-07-26	Alnylam Pharmaceuticals, Inc.	Pegylated lipids and their use for drug delivery
US9045749B2 (en)	2011-01-14	2015-06-02	The General Hospital Corporation	Methods targeting miR-128 for regulating cholesterol/lipid metabolism
TWI593416B (zh)	2011-02-02	2017-08-01	艾克厘德製藥公司	利用針對結締組織生長因子（ｃｔｇｆ）目標之反義化合物治療瘢痕或肥厚性疤痕之方法
WO2012113775A1 (en)	2011-02-21	2012-08-30	University Of Zurich	Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
JP6108628B2 (ja)	2011-03-29	2017-04-05	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｔｍｐｒｓｓ６遺伝子の発現を阻害する組成物および方法
RU2620980C2 (ru)	2011-06-09	2017-05-30	Курна, Инк.	Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
CN103890000B (zh)	2011-06-21	2017-09-01	阿尔尼拉姆医药品有限公司	血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
RU2631805C2 (ru)	2011-06-21	2017-09-26	Элнилэм Фармасьютикалз, Инк.	Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
EP3388068A1 (de)	2011-06-21	2018-10-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
EP3366312A1 (de)	2011-06-23	2018-08-29	Alnylam Pharmaceuticals, Inc.	Serpina 1 sirnas: materialzusammensetzungen und verfahren zur behandlung
US20140328811A1 (en)	2011-08-01	2014-11-06	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
CA2847698C (en)	2011-09-14	2020-09-01	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
JP6129844B2 (ja)	2011-09-14	2017-05-17	ラナセラピューティクスインコーポレイテッド	多量体オリゴヌクレオチド化合物
WO2013049328A1 (en)	2011-09-27	2013-04-04	Alnylam Pharmaceuticals, Inc.	Di-aliphatic substituted pegylated lipids
BR112014008925A2 (pt)	2011-10-11	2020-10-27	The Brigham And Women's Hospital, Inc.	micro rnas em distúrbios de neurodegenerativos
DK2790736T3 (en)	2011-12-12	2018-05-07	Oncoimmunin Inc	In vivo delivery of oligonucleotides
RS63244B1 (sr)	2011-12-16	2022-06-30	Modernatx Inc	Kompozicije modifikovane mrna
US20150031750A1 (en)	2012-03-15	2015-01-29	The Scripps Research Institute	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2833892A4 (de)	2012-04-02	2016-07-20	Moderna Therapeutics Inc	Modifizierte polynukleotide zur herstellung von in der onkologie nützlichen proteinen und peptiden
CN108949772A (zh)	2012-04-02	2018-12-07	现代泰克斯公司	用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
CN104704122A (zh)	2012-04-20	2015-06-10	艾珀特玛治疗公司	产热的miRNA调节剂
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
TW201408690A (zh) *	2012-05-05	2014-03-01	Academia Sinica	二氨基苯甲酸或鄰苯二胺共軛的胜肽作為功能性的醣類標幟劑
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
CA2873809A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics, Inc.	Compositions and methods for modulating gene expression
US10059941B2 (en)	2012-05-16	2018-08-28	Translate Bio Ma, Inc.	Compositions and methods for modulating SMN gene family expression
US20150216892A1 (en)	2012-08-03	2015-08-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
ES2921623T3 (es)	2012-11-26	2022-08-30	Modernatx Inc	ARN modificado terminalmente
WO2014113089A2 (en)	2013-01-17	2014-07-24	Moderna Therapeutics, Inc.	Signal-sensor polynucleotides for the alteration of cellular phenotypes
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
WO2014159813A1 (en)	2013-03-13	2014-10-02	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
US10258698B2 (en)	2013-03-14	2019-04-16	Modernatx, Inc.	Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
HUE034987T2 (en)	2013-03-14	2018-05-02	Alnylam Pharmaceuticals Inc	C5 complementary component IRNS preparations and methods for their use
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
CA2918194C (en)	2013-03-27	2022-12-06	The General Hospital Corporation	Methods and agents for treating alzheimer's disease
WO2014172698A1 (en)	2013-04-19	2014-10-23	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation nucleic acids through nonsense mediated decay
PT2999785T (pt)	2013-05-22	2018-07-09	Alnylam Pharmaceuticals Inc	Composições de irna de serpina1 e métodos de uso das mesmas
US20160129089A1 (en)	2013-06-13	2016-05-12	Antisense Therapeutics Ltd	Combination therapy
HRP20211563T1 (hr)	2013-07-11	2022-01-07	Modernatx, Inc.	Pripravci koji sadrže sintetske polinukleotide koji kodiraju proteine srodne crispr-u i sintetske sgrna, te postupci njihove uporabe
AU2014306271A1 (en)	2013-08-08	2016-03-24	The Scripps Research Institute	A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
CA2923029A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Chimeric polynucleotides
EP3041938A1 (de)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Kreisförmige polynukleotide
EP3052626A1 (de)	2013-10-02	2016-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
AU2014329452B2 (en)	2013-10-03	2019-06-20	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
UA124961C2 (uk)	2013-10-04	2021-12-22	Елнілем Фармасьютикалз, Інк.	ДВОНИТКОВА РИБОНУКЛЕЇНОВА КИСЛОТА (dsRNA) ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ALAS1
CN107075515B (zh)	2013-11-22	2020-10-30	米纳治疗有限公司	C/EBPα组合物和使用方法
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
IL282401B (en)	2013-12-12	2022-08-01	Alnylam Pharmaceuticals Inc	Complementary component irna compositions and methods for using them
CA2937539A1 (en)	2014-02-04	2015-08-13	Genentech, Inc.	Mutant smoothened and methods of using the same
EP3960860A3 (de)	2014-02-11	2022-06-08	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
TWI638047B (zh)	2014-04-09	2018-10-11	史基普研究協會	藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
EP4162940A1 (de)	2014-04-17	2023-04-12	Biogen MA Inc.	Zusammensetzungen und verfahren zur modulation der smn2-aufspaltung in einem patienten
WO2015171918A2 (en)	2014-05-07	2015-11-12	Louisiana State University And Agricultural And Mechanical College	Compositions and uses for treatment thereof
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
AU2015264038B2 (en)	2014-05-22	2021-02-11	Alnylam Pharmaceuticals, Inc.	Angiotensinogen (AGT) iRNA compositions and methods of use thereof
HRP20220379T1 (hr)	2014-06-10	2022-05-27	Erasmus University Medical Center Rotterdam	Antisense oligonukleotidi korisni u liječenju pompeove bolesti
BR112016029024A8 (pt)	2014-06-11	2021-07-20	Univ Texas	composto, composição farmacêutica e uso
EP3161159B1 (de)	2014-06-25	2020-08-05	The General Hospital Corporation	Targeting von humanem satellit ii (hsatii)
CA2955250A1 (en)	2014-07-16	2016-01-21	Moderna Therapeutics, Inc.	Chimeric polynucleotides
WO2016014846A1 (en)	2014-07-23	2016-01-28	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of intrabodies
BR112017001860A2 (pt)	2014-07-31	2018-02-27	Uab Research Foundation	peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
US10385343B2 (en)	2014-08-29	2019-08-20	Children's Medical Center Corporation	Methods and compositions for the treatment of cancer
WO2016040589A1 (en)	2014-09-12	2016-03-17	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
EP3198012B1 (de)	2014-09-26	2019-09-04	University of Massachusetts	Rna-modulierende stoffe
WO2016061487A1 (en)	2014-10-17	2016-04-21	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3904519A1 (de)	2014-10-30	2021-11-03	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
JOP20200092A1 (ar)	2014-11-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
AU2015350120B2 (en)	2014-11-17	2021-05-27	Alnylam Pharmaceuticals, Inc.	Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
WO2016081911A2 (en)	2014-11-21	2016-05-26	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016094342A1 (en)	2014-12-08	2016-06-16	The Board Of Regents Of The University Of Texas System	Lipocationic polymers and uses thereof
WO2016100716A1 (en)	2014-12-18	2016-06-23	Vasant Jadhav	Reversirtm compounds
EP3247988A4 (de)	2015-01-23	2018-12-19	Vanderbilt University	Robustes interferometer und verfahren zur verwendung davon
EP3256487A4 (de)	2015-02-09	2018-07-18	Duke University	Zusammensetzungen und verfahren zur epigenombearbeitung
CA2976445A1 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
US20180200387A1 (en)	2015-02-23	2018-07-19	Crispr Therapeutics Ag	Materials and methods for treatment of human genetic diseases including hemoglobinopathies
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
WO2016164746A1 (en)	2015-04-08	2016-10-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
CA2982853C (en)	2015-04-17	2022-06-07	University Health Network	Texaphyrin-phospholipid conjugates and methods of preparing same
EP3307388B1 (de)	2015-06-10	2022-06-22	Ekos Corporation	Ultraschallkatheter
WO2016201301A1 (en)	2015-06-12	2016-12-15	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
WO2016210241A1 (en)	2015-06-26	2016-12-29	Beth Israel Deaconess Medical Center, Inc.	Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
US10590425B2 (en)	2015-06-29	2020-03-17	Caris Science, Inc.	Therapeutic oligonucleotides
US10494632B2 (en)	2015-07-10	2019-12-03	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
AU2016295168B2 (en)	2015-07-17	2021-08-19	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
AU2016298317B2 (en)	2015-07-28	2021-02-18	Caris Science, Inc.	Targeted oligonucleotides
CN114525280A (zh)	2015-09-02	2022-05-24	阿尔尼拉姆医药品有限公司	程序性细胞死亡1配体1（PD-L1）的iRNA组合物及其使用方法
JP7041616B2 (ja)	2015-09-14	2022-03-24	ザボードオブリージェンツオブザユニバーシティーオブテキサスシステム	リポカチオン性デンドリマーおよびその使用
EP3353297A1 (de)	2015-09-24	2018-08-01	Crispr Therapeutics AG	Neuartige familie von rna-programmierbaren endonukleasen und deren verwendung in der genomeditierung und anderen anwendungen
JP2019507579A (ja)	2015-10-28	2019-03-22	クリスパーセラピューティクスアーゲー	デュシェンヌ型筋ジストロフィーの処置のための材料および方法
ES2938883T3 (es)	2015-11-05	2023-04-17	Los Angeles Childrens Hospital	Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
WO2017077386A1 (en)	2015-11-06	2017-05-11	Crispr Therapeutics Ag	Materials and methods for treatment of glycogen storage disease type 1a
CA3005878A1 (en)	2015-11-19	2017-05-26	The Brigham And Women's Hospital, Inc.	Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2017093804A2 (en)	2015-12-01	2017-06-08	Crispr Therapeutics Ag	Materials and methods for treatment of alpha-1 antitrypsin deficiency
AU2015416656B2 (en)	2015-12-07	2023-02-23	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for Pompe disease
US11761007B2 (en)	2015-12-18	2023-09-19	The Scripps Research Institute	Production of unnatural nucleotides using a CRISPR/Cas9 system
US20210260219A1 (en)	2015-12-23	2021-08-26	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
US10627396B2 (en)	2016-01-29	2020-04-21	Vanderbilt University	Free-solution response function interferometry
EP3411078A1 (de)	2016-02-02	2018-12-12	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn-syndrom
CN109071625A (zh)	2016-02-04	2018-12-21	柯瑞斯公司	平滑化突变体和其使用方法
WO2017141109A1 (en)	2016-02-18	2017-08-24	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
EP3419665A4 (de)	2016-02-25	2019-10-16	The Brigham and Women's Hospital, Inc.	Behandlungsverfahren für fibrose-targeting-smoc2
US11083799B2 (en)	2016-03-16	2021-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
JP2019516393A (ja)	2016-03-18	2019-06-20	カリスサイエンスインコーポレイテッド	オリゴヌクレオチドプローブおよびその使用
BR112018071321A2 (pt)	2016-04-18	2019-02-26	Crispr Therapeutics Ag	materiais e métodos para tratamento de hemoglobinopatias
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
CN109414408B (zh)	2016-05-16	2022-03-29	得克萨斯州大学系统董事会	阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
AU2017271579B2 (en)	2016-05-25	2023-10-19	Caris Science, Inc.	Oligonucleotide probes and uses thereof
JP2019518028A (ja)	2016-06-10	2019-06-27	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
EP3475295B1 (de)	2016-06-24	2022-08-10	The Scripps Research Institute	Neuartiger nukleosid-triphosphat-transporter und verwendungen davon
US11174469B2 (en)	2016-06-29	2021-11-16	Crispr Therapeutics Ag	Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
EP3478828A1 (de)	2016-06-29	2019-05-08	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von friedreich-ataxie und anderen verwandten erkrankungen
WO2018002812A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
US11459587B2 (en)	2016-07-06	2022-10-04	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
EP3481856A1 (de)	2016-07-06	2019-05-15	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von schmerzbedingten erkrankungen
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
AU2017296195A1 (en)	2016-07-11	2019-01-24	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
CA3037046A1 (en)	2016-10-31	2018-05-03	University Of Massachusetts	Targeting microrna-101-3p in cancer therapy
TW202313978A (zh)	2016-11-23	2023-04-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
WO2018111834A1 (en)	2016-12-13	2018-06-21	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
KR20230166146A (ko)	2016-12-16	2023-12-06	알닐람 파마슈티칼스 인코포레이티드	트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
BR112019014841A2 (pt)	2017-01-23	2020-04-28	Regeneron Pharma	rna guia, uso do rna guia, rna antissentido, sirna ou shrna, uso do rna antissentido, do sirna ou do shrna, ácido nucleico isolado, vetor, composição, célula, e, métodos para modificar um gene hsd17b13 em uma célula, para diminuir a expressão de um gene hsd17b13 em uma célula, para modificar uma célula e para tratar um indivíduo que não é portador da variante de hsd17b13
WO2018154439A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
AU2018224387A1 (en)	2017-02-22	2019-09-05	Crispr Therapeutics Ag	Compositions and methods for gene editing
EP3585807A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung der parkinson-krankheit im frühstadium (park1) und anderer zustände oder störungen im zusammenhang mit dem synuclein-alpha (snca)-gen
EP3585900B1 (de)	2017-02-22	2022-12-21	CRISPR Therapeutics AG	Materialien und methoden zur behandlung von spinocerebellar ataxia typ 2 (sca2) und anderen spinocerebellar ataxia typ 2 protein (atxn2) gen verwandten erkrankungen oder störungen
WO2018154459A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
KR20200015895A (ko)	2017-04-18	2020-02-13	알닐람 파마슈티칼스 인코포레이티드	B형 간염 바이러스 (hbv)에 감염된 대상체의 치료 방법
US20200384115A1 (en)	2017-04-21	2020-12-10	The Broad Institute , Inc.	Targeted delivery to beta cells
AU2018367896B2 (en)	2017-05-12	2023-06-01	Crispr Therapeutics Ag	Materials and methods for engineering cells and uses thereof in immuno-oncology
AU2018300069A1 (en)	2017-07-11	2020-02-27	Synthorx, Inc.	Incorporation of unnatural nucleotides and methods thereof
WO2019014530A1 (en)	2017-07-13	2019-01-17	Alnylam Pharmaceuticals Inc.	LACTATE DEHYDROGENASE A (LDHA) RNAI COMPOSITIONS AND METHODS OF USE
TWI757528B (zh)	2017-08-03	2022-03-11	美商欣爍克斯公司	用於增生及感染性疾病治療之細胞激素結合物
EP3679139B1 (de)	2017-09-08	2022-11-02	MiNA Therapeutics Limited	Stabilisierte hnf4a-sara-zusammensetzungen und verwendungsverfahren
WO2019048645A1 (en)	2017-09-08	2019-03-14	Mina Therapeutics Limited	STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
SG11202003464VA (en)	2017-10-17	2020-05-28	Crispr Therapeutics Ag	Compositions and methods for gene editing for hemophilia a
EP3701029A1 (de)	2017-10-26	2020-09-02	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
WO2019089922A1 (en)	2017-11-01	2019-05-09	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof
EP3707155A2 (de)	2017-11-09	2020-09-16	Vertex Pharmaceuticals Incorporated	Crispr/cas-systeme für die behandlung von dmd
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
WO2019102381A1 (en)	2017-11-21	2019-05-31	Casebia Therapeutics Llp	Materials and methods for treatment of autosomal dominant retinitis pigmentosa
CN111629747A (zh)	2017-12-05	2020-09-04	沃泰克斯药物股份有限公司	Crispr-cas9修饰的cd34+人血色素干细胞和祖细胞及其用途
MA51138A (fr)	2017-12-14	2020-10-21	Bayer Healthcare Llc	Nouveaux systèmes d'endonucléases arn-programmables et leurs utilisations dans l'édition de génome et d'autres applications
JP2021508491A (ja)	2017-12-18	2021-03-11	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	高移動度グループボックス−１（ＨＭＧＢ１）ｉＲＮＡ組成物及びその使用方法
WO2019123430A1 (en)	2017-12-21	2019-06-27	Casebia Therapeutics Llp	Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
AU2018393050A1 (en)	2017-12-21	2020-06-18	Bayer Healthcare Llc	Materials and methods for treatment of Usher Syndrome Type 2A
US20210254057A1 (en)	2018-01-12	2021-08-19	Crispr Therapeutics Ag	Compositions and methods for gene editing by targeting transferrin
US20190233816A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
WO2019150203A1 (en)	2018-02-05	2019-08-08	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
EP3749767A1 (de)	2018-02-05	2020-12-16	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
EP3752616A1 (de)	2018-02-16	2020-12-23	CRISPR Therapeutics AG	Zusammensetzungen und verfahren zur geneditierung durch targeting von fibrinogen-alpha
KR20200127207A (ko)	2018-02-26	2020-11-10	신톡스, 인크.	Il-15 접합체 및 이의 용도
EP3768834A1 (de)	2018-03-19	2021-01-27	CRISPR Therapeutics AG	Neuartige rna-programmierbare endonukleasesysteme und verwendungen davon
CA3095545A1 (en)	2018-03-30	2019-10-03	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activaton of t cell-mediated immunity
CA3096274A1 (en)	2018-04-06	2019-10-10	Children's Medical Center Corporation	Compositions and methods for somatic cell reprogramming and modulating imprinting
EP3775211B1 (de)	2018-04-12	2023-04-05	MiNA Therapeutics Limited	Sirt1-sarna kompositionen und methoden zu deren verwendung
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
BR112020022546A8 (pt)	2018-05-07	2022-05-17	Alnylam Pharmaceuticals Inc	Entrega extra-hepática
TW202016304A (zh)	2018-05-14	2020-05-01	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
SG11202100715WA (en)	2018-08-13	2021-02-25	Alnylam Pharmaceuticals Inc	HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
TW202020157A (zh)	2018-08-16	2020-06-01	美商艾爾妮蘭製藥公司	用於抑制lect2基因表現之組合物及方法
EP3843845A4 (de)	2018-08-29	2022-05-11	University Of Massachusetts	Hemmung von proteinkinasen zur behandlung von friedreich-ataxie
JP2022500003A (ja)	2018-09-18	2022-01-04	アルナイラムファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc.	ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法
WO2020069055A1 (en)	2018-09-28	2020-04-02	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
CN113366106A (zh)	2018-10-17	2021-09-07	克里斯珀医疗股份公司	用于递送转基因的组合物和方法
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
TW202039000A (zh)	2018-12-20	2020-11-01	瑞士商休曼斯生物醫藥公司	組合ｈｂｖ療法
AU2019406186A1 (en)	2018-12-20	2021-07-15	Praxis Precision Medicines, Inc.	Compositions and methods for the treatment of KCNT1 related disorders
CN113557023A (zh)	2019-01-16	2021-10-26	建新公司	Serpinc1 iRNA组合物及其使用方法
AU2020218203A1 (en)	2019-02-06	2021-08-26	Synthorx, Inc.	IL-2 conjugates and methods of use thereof
CA3129532A1 (en)	2019-02-15	2020-08-20	Crispr Therapeutics Ag	Gene editing for hemophilia a with improved factor viii expression
WO2020171889A1 (en)	2019-02-19	2020-08-27	University Of Rochester	Blocking lipid accumulation or inflammation in thyroid eye disease
MA55297A (fr)	2019-03-12	2022-01-19	Bayer Healthcare Llc	Nouveaux systèmes d'endonucléase à arn programmable haute fidélité et leurs utilisations
US20220211740A1 (en)	2019-04-12	2022-07-07	Mina Therapeutics Limited	Sirt1-sarna compositions and methods of use
CN114126628A (zh)	2019-05-13	2022-03-01	维尔生物科技有限公司	用于治疗乙型肝炎病毒(hbv)感染的组合物及方法
JP2022532652A (ja)	2019-05-17	2022-07-15	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの経口送達
TW202113078A (zh)	2019-06-14	2021-04-01	美商史基普研究協會	於半合成生物體中複製、轉錄及轉譯之試劑及方法
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4007812A1 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
CN114555128A (zh)	2019-08-15	2022-05-27	新索思股份有限公司	采用il-2缀合物的免疫肿瘤学组合疗法
CN114585633A (zh)	2019-08-19	2022-06-03	米纳治疗有限公司	寡核苷酸缀合物组合物和使用方法
MX2022002053A (es)	2019-08-23	2022-03-17	Synthorx Inc	Conjugados de il-15 y sus usos.
US20220290152A1 (en)	2019-09-03	2022-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
KR20220061158A (ko)	2019-09-10	2022-05-12	신톡스, 인크.	자가면역질환을 치료하기 위한 il-2 접합체 및 사용 방법
US20220389429A1 (en)	2019-10-04	2022-12-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
EP4045652A1 (de)	2019-10-18	2022-08-24	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
TW202134435A (zh)	2019-10-22	2021-09-16	美商阿尼拉製藥公司	補體成分ｃ３ｉｒｎａ組成物及其使用方法
EP4051796A1 (de)	2019-11-01	2022-09-07	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
TW202132567A (zh)	2019-11-01	2021-09-01	美商阿尼拉製藥公司	亨汀頓蛋白（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
TW202131952A (zh)	2019-11-04	2021-09-01	美商欣爍克斯公司	介白素10接合物及其用途
JP2023500681A (ja)	2019-11-06	2023-01-10	アルニラムファーマスーティカルズインコーポレイテッド	肝臓外送達
WO2021092145A1 (en)	2019-11-06	2021-05-14	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
MX2022005692A (es)	2019-11-13	2022-06-08	Alnylam Pharmaceuticals Inc	Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt).
EP4061945A1 (de)	2019-11-22	2022-09-28	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
KR20220115995A (ko)	2019-12-13	2022-08-19	알닐람 파마슈티칼스 인코포레이티드	인간 염색체 ９ 개방 판독 프레임 72 (C9orf72) iRNA 제제 조성물 및 이의 사용 방법
WO2021126734A1 (en)	2019-12-16	2021-06-24	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2021122944A1 (en)	2019-12-18	2021-06-24	Alia Therapeutics Srl	Compositions and methods for treating retinitis pigmentosa
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
IL295445A (en)	2020-02-10	2022-10-01	Alnylam Pharmaceuticals Inc	Preparations and methods for silencing vegf-a expression
MX2022010052A (es)	2020-02-18	2022-09-05	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) contra la apolipoproteina c3 (apoc3) y metodos para su uso.
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
WO2021178736A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021178778A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of transthyretin (ttr)
EP4121534A1 (de)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
WO2021195307A1 (en)	2020-03-26	2021-09-30	Alnylam Pharmaceuticals, Inc.	Coronavirus irna compositions and methods of use thereof
EP4127171A2 (de)	2020-03-30	2023-02-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
CA3179411A1 (en)	2020-04-06	2021-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing myoc expression
CN116134135A (zh)	2020-04-07	2023-05-16	阿尔尼拉姆医药品有限公司	用于沉默scn9a表达的组合物和方法
WO2021206922A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
WO2021206917A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA3181400A1 (en)	2020-04-27	2021-11-04	Alnylam Pharmaceuticals, Inc.	Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
WO2021222549A1 (en)	2020-04-30	2021-11-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
EP4150089A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von retinosin 1 (rs1)
WO2021231675A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231692A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
EP4150087A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
EP4153746A1 (de)	2020-05-21	2023-03-29	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
BR112022023465A2 (pt)	2020-05-22	2023-01-10	Wave Life Sciences Ltd	Agente de rnai de fita dupla (dsrnai), composição de oligonucleotídeo quiralmente controlada, oligonucleotídeo de fita dupla, método para reduzir o nível e/ou a atividade de um transcrito ou uma proteína codificada pelo mesmo, e método para supressão específica quanto ao alelo de um transcrito de uma sequência de ácidos nucleicos
AR122534A1 (es)	2020-06-03	2022-09-21	Triplet Therapeutics Inc	Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
WO2021252557A1 (en)	2020-06-09	2021-12-16	Alnylam Pharmaceuticals, Inc.	Rnai compositions and methods of use thereof for delivery by inhalation
BR112022024420A2 (pt)	2020-06-18	2023-01-17	Alnylam Pharmaceuticals Inc	Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas
AU2021296848A1 (en)	2020-06-24	2023-02-09	Humabs Biomed Sa	Engineered hepatitis B virus neutralizing antibodies and uses thereof
IL299074A (en)	2020-06-25	2023-02-01	Synthorx Inc	Immuno-oncology therapeutic combination with IL-2 and anti-AGFR antibody conjugates
IL299771A (en)	2020-07-10	2023-03-01	Inst Nat Sante Rech Med	Methods and compounds for the treatment of epilepsy
WO2022011214A1 (en)	2020-07-10	2022-01-13	Alnylam Pharmaceuticals, Inc.	Circular sirnas
WO2022066847A1 (en)	2020-09-24	2022-03-31	Alnylam Pharmaceuticals, Inc.	Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
US20230392134A1 (en)	2020-09-30	2023-12-07	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis
EP4225917A1 (de)	2020-10-05	2023-08-16	Alnylam Pharmaceuticals, Inc.	G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
CA3194859A1 (en)	2020-10-09	2022-04-14	Carolina E. CAFFARO	Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
KR20230084204A (ko)	2020-10-09	2023-06-12	신톡스, 인크.	Il-2 콘쥬게이트를 사용한 면역 종양학 치료법
WO2022087329A1 (en)	2020-10-23	2022-04-28	Alnylam Pharmaceuticals, Inc.	Mucin 5b (muc5b) irna compositions and methods of use thereof
IL302709A (en)	2020-11-13	2023-07-01	Alnylam Pharmaceuticals Inc	Coagulation factor iRNA compositions (F5) and methods of using them
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
EP4271696A2 (de)	2020-12-31	2023-11-08	Alnylam Pharmaceuticals, Inc.	Oligonukleotid-prodrugs auf basis von mit cyclischem disulfid modifiziertem phosphat
WO2022147223A2 (en)	2020-12-31	2022-07-07	Alnylam Pharmaceuticals, Inc.	2'-modified nucleoside based oligonucleotide prodrugs
EP4274896A1 (de)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202302148A (zh)	2021-02-12	2023-01-16	美商欣爍克斯公司	使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法
JP2024508714A (ja)	2021-02-12	2024-02-28	アルナイラムファーマシューティカルズ，インコーポレイテッド	スーパーオキシドジスムターゼ１－（ＳＯＤ１－）関連神経変性疾患を治療または予防するためのスーパーオキシドジスムターゼ１（ＳＯＤ１）ｉＲＮＡ組成物およびその使用方法
WO2022174101A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Skin cancer combination therapy with il-2 conjugates and cemiplimab
JP2024509783A (ja)	2021-02-25	2024-03-05	アルナイラムファーマシューティカルズ，インコーポレイテッド	プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
KR20230150844A (ko)	2021-02-26	2023-10-31	알닐람 파마슈티칼스 인코포레이티드	케토헥소키나아제(KHK) iRNA 조성물 및 이의 사용 방법
CA3212128A1 (en)	2021-03-04	2022-09-09	Alnylam Pharmaceuticals, Inc.	Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
WO2022192519A1 (en)	2021-03-12	2022-09-15	Alnylam Pharmaceuticals, Inc.	Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
AU2022246144A1 (en)	2021-03-26	2023-09-21	Mina Therapeutics Limited	Tmem173 sarna compositions and methods of use
WO2022212231A2 (en)	2021-03-29	2022-10-06	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt) irna agent compositions and methods of use thereof
WO2022212153A1 (en)	2021-04-01	2022-10-06	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
JP2024516168A (ja)	2021-04-22	2024-04-12	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	がんを治療するための組成物および方法
IL307926A (en)	2021-04-26	2023-12-01	Alnylam Pharmaceuticals Inc	Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them
EP4330396A1 (de)	2021-04-29	2024-03-06	Alnylam Pharmaceuticals, Inc.	Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022245583A1 (en)	2021-05-18	2022-11-24	Alnylam Pharmaceuticals, Inc.	Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
EP4341405A1 (de)	2021-05-20	2024-03-27	Korro Bio, Inc.	Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
EP4347823A1 (de)	2021-06-02	2024-04-10	Alnylam Pharmaceuticals, Inc.	Patin-ähnliche phospholipasedomäne mit 3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202313679A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
CN117561334A (zh)	2021-06-04	2024-02-13	阿尔尼拉姆医药品有限公司	人染色体9开放阅读框72（C9ORF72）iRNA药剂组合物和其使用方法
WO2022260939A2 (en)	2021-06-08	2022-12-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
IL308896A (en)	2021-06-11	2024-01-01	Bayer Ag	Programmable type V RNA endoclase systems
WO2023278410A1 (en)	2021-06-29	2023-01-05	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
KR20240026203A (ko)	2021-06-30	2024-02-27	알닐람 파마슈티칼스 인코포레이티드	안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
WO2023283403A2 (en)	2021-07-09	2023-01-12	Alnylam Pharmaceuticals, Inc.	Bis-rnai compounds for cns delivery
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
WO2023003805A1 (en)	2021-07-19	2023-01-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
AU2022314619A1 (en)	2021-07-21	2024-01-04	Alnylam Pharmaceuticals, Inc.	Metabolic disorder-associated target gene irna compositions and methods of use thereof
WO2023003995A1 (en)	2021-07-23	2023-01-26	Alnylam Pharmaceuticals, Inc.	Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2023009687A1 (en)	2021-07-29	2023-02-02	Alnylam Pharmaceuticals, Inc.	3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
WO2023014677A1 (en)	2021-08-03	2023-02-09	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof
KR20240042016A (ko)	2021-08-04	2024-04-01	알닐람 파마슈티칼스 인코포레이티드	안지오텐시노겐(AGT)을 침묵화하기 위한 iRNA 조성물 및 방법
IL310407A (en)	2021-08-13	2024-03-01	Alnylam Pharmaceuticals Inc	Factor XII (F12) IRNA compositions and methods of using them
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
WO2023044370A2 (en)	2021-09-17	2023-03-23	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing complement component 3 (c3)
CA3232420A1 (en)	2021-09-20	2023-03-23	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
WO2023064530A1 (en)	2021-10-15	2023-04-20	Alnylam Pharmaceuticals, Inc.	Extra-hepatic delivery irna compositions and methods of use thereof
CA3234835A1 (en)	2021-10-22	2023-04-27	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
CA3234636A1 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
TW202334418A (zh)	2021-10-29	2023-09-01	美商艾拉倫製藥股份有限公司	杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
WO2023099884A1 (en)	2021-12-01	2023-06-08	Mina Therapeutics Limited	Pax6 sarna compositions and methods of use
WO2023122573A1 (en)	2021-12-20	2023-06-29	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023118349A1 (en)	2021-12-21	2023-06-29	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
WO2023118068A1 (en)	2021-12-23	2023-06-29	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
WO2023141314A2 (en)	2022-01-24	2023-07-27	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023170435A1 (en)	2022-03-07	2023-09-14	Mina Therapeutics Limited	Il10 sarna compositions and methods of use
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
WO2023220744A2 (en)	2022-05-13	2023-11-16	Alnylam Pharmaceuticals, Inc.	Single-stranded loop oligonucleotides
CN114790161B (zh) *	2022-05-16	2023-12-01	百顺药业有限公司	4-甲氧基羰基乙基-3-甲基-2-吡咯醛的合成方法及其中间体
WO2023237587A1 (en)	2022-06-10	2023-12-14	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2024006999A2 (en)	2022-06-30	2024-01-04	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
WO2024059165A1 (en)	2022-09-15	2024-03-21	Alnylam Pharmaceuticals, Inc.	17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2024056880A2 (en)	2022-09-16	2024-03-21	Alia Therapeutics Srl	Enqp type ii cas proteins and applications thereof
WO2024073732A1 (en)	2022-09-30	2024-04-04	Alnylam Pharmaceuticals, Inc.	Modified double-stranded rna agents

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4318825A (en) *	1979-08-15	1982-03-09	Frame Robert R	Catalytic composite, and method of manufacture
US4957939A (en) *	1981-07-24	1990-09-18	Schering Aktiengesellschaft	Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) *	1981-07-24	1987-03-03	Schering Aktiengesellschaft	Diagnostic media
US4613322A (en) *	1982-12-08	1986-09-23	Edelson Richard Leslie	Method and system for externally treating the blood
FR2540122B1 (fr) *	1983-01-27	1985-11-29	Centre Nat Rech Scient	Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
JPS61275228A (ja) *	1985-03-14	1986-12-05	バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド	治療用タンパク組成物中のビ−ルスの光動的不活性化
US4977177A (en) *	1985-04-30	1990-12-11	Nippon Petrochemicals Company, Ltd.	Tetrapyrrole polyaminomonocarboxylic acid therapeutic agents
US4880008A (en) *	1985-05-08	1989-11-14	The General Hospital Corporation	Vivo enhancement of NMR relaxivity
US4899755A (en) *	1985-05-08	1990-02-13	The General Hospital Corporation	Hepatobiliary NMR contrast agents
US4772681A (en) *	1986-01-17	1988-09-20	Hamari Chemicals, Ltd.	Porphyrin derivatives
US5242797A (en) *	1986-03-21	1993-09-07	Myron J. Block	Nucleic acid assay method
US4915683A (en) *	1986-11-21	1990-04-10	The Medical College Of Wisconsin, Inc.	Antiviral method, agents and apparatus
US4883790A (en) *	1987-01-20	1989-11-28	University Of British Columbia	Wavelength-specific cytotoxic agents
US4878891A (en) *	1987-06-25	1989-11-07	Baylor Research Foundation	Method for eradicating infectious biological contaminants in body tissues
WO1990001208A1 (en) *	1988-07-28	1990-02-08	Best Industries, Inc.	Device and method for encapsulating radioactive materials
US5162509A (en) *	1989-03-06	1992-11-10	Board Of Regents, The University Of Texas System	Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US4935498A (en) *	1989-03-06	1990-06-19	Board Of Regents, The University Of Texas System	Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5041078A (en) *	1989-03-06	1991-08-20	Baylor Research Foundation, A Nonprofit Corporation Of The State Of Texas	Photodynamic viral deactivation with sapphyrins
US5272142A (en) *	1989-03-06	1993-12-21	Board Of Regents, The University Of Texas System	Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles and methods for treating tumors
US5252720A (en) *	1989-03-06	1993-10-12	Board Of Regents, The University Of Texas System	Metal complexes of water soluble texaphyrins
US5256399A (en) *	1989-03-06	1993-10-26	Board Of Regents, The University Of Texas System	Aromatic pentadentate expanded porphyrins in magnetic resonance imaging
US4959363A (en) *	1989-06-23	1990-09-25	Sterling Drug Inc.	Quinolonecarboxamide compounds, their preparation and use as antivirals.
FR2650761B1 (fr) *	1989-08-10	1994-03-04	Elf Aquitaine Ste Nale	Catalyseur d'oxydation a base de metalloporphyrine sur support
US5159065A (en) *	1989-12-21	1992-10-27	Board Of Regents, The University Of Texas System	Sapphyrins, derivatives and syntheses
US5272056A (en) *	1991-01-03	1993-12-21	The Research Foundation Of State University Of New York	Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
US5371199B1 (en) *	1992-08-14	1995-12-26	Univ Pennsylvania	Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor

1994
- 1994-02-15 US US08/196,964 patent/US5599923A/en not_active Expired - Lifetime
1995
- 1995-02-15 DE DE69526782T patent/DE69526782T2/de not_active Expired - Fee Related
- 1995-02-15 ES ES95911776T patent/ES2173951T3/es not_active Expired - Lifetime
- 1995-02-15 DK DK95911776T patent/DK0745085T3/da active
- 1995-02-15 PT PT95911776T patent/PT745085E/pt unknown
- 1995-02-15 AU AU19217/95A patent/AU688008B2/en not_active Ceased
- 1995-02-15 NZ NZ282185A patent/NZ282185A/en unknown
- 1995-02-15 EP EP95911776A patent/EP0745085B1/de not_active Expired - Lifetime
- 1995-02-15 CA CA002182960A patent/CA2182960A1/en not_active Abandoned
- 1995-02-15 KR KR1019960704419A patent/KR970701193A/ko not_active Application Discontinuation
- 1995-02-15 WO PCT/US1995/001996 patent/WO1995021845A1/en active IP Right Grant
- 1995-02-15 AT AT95911776T patent/ATE217874T1/de not_active IP Right Cessation
- 1995-02-15 JP JP7521434A patent/JPH10500659A/ja not_active Ceased
- 1995-06-02 US US08/459,333 patent/US5599928A/en not_active Expired - Fee Related
1996
- 1996-08-14 NO NO963396A patent/NO308473B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
JPH10500659A (ja)	1998-01-20
PT745085E (pt)	2002-10-31
US5599928A (en)	1997-02-04
NZ282185A (en)	1998-03-25
NO963396D0 (no)	1996-08-14
US5599923A (en)	1997-02-04
CA2182960A1 (en)	1995-08-17
ATE217874T1 (de)	2002-06-15
DK0745085T3 (da)	2002-06-17
AU1921795A (en)	1995-08-29
DE69526782T2 (de)	2003-03-06
WO1995021845A1 (en)	1995-08-17
NO308473B1 (no)	2000-09-18
ES2173951T3 (es)	2002-11-01
AU688008B2 (en)	1998-03-05
EP0745085B1 (de)	2002-05-22
EP0745085A1 (de)	1996-12-04
NO963396L (no)	1996-10-14
KR970701193A (ko)	1997-03-17

Legal Events

Date	Code	Title
2002-12-12	8332	No legal effect for de
2003-01-02	8370	Indication related to discontinuation of the patent is to be deleted
2003-06-18	8364	No opposition during term of opposition
2007-12-13	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
ATE217874T1 (de)	2002-06-15	Texaphyrin metallkomplexe mit verbesserten funktionellen gruppen
GEP20074185B (en)	2007-08-10	Incclusion complexs of aryl- heterocyclic salts
BG104812A (en)	2001-06-29	New dihydropyrimidines
AU2291097A (en)	1997-10-17	Novel phenanthridines substituted in the 6 position
AU2795000A (en)	2000-07-12	Epothilone derivatives and their use as antitumor agents
AU3499395A (en)	1996-03-22	Ionene polymers containing biologically-active anions
BG105784A (en)	2002-02-28	Triazole compounds with dopamine-d3-receptor affinity
NZ335383A (en)	2000-10-27	Epothilone C,D,E and F for plant protection and cytostatic effects shown in kidney cells
PL346875A1 (en)	2002-03-11	Oral care compositions
DE69807074T2 (de)	2003-04-03	Substituierte 1,2,4-triazolo[3,4,-a]phthalazin-derivate als gaba-alpha 5-liganden
PT882021E (pt)	2003-07-31	Novas fenantridinas
MXPA03008755A (es)	2004-02-18	Derivados de 2-amino-propanol.
PL338339A1 (en)	2000-10-23	Novel derivatives of tetrazole
YU19499A (sh)	2001-09-28	Benzonaftiridini kao bronhijalni terapeutici
AU6203399A (en)	2000-05-01	Polyamide composition stabilized with copper complexes and organic halogen compounds
MX9805499A (es)	1998-11-30	Compuestos de azacicloheptano y diazacicloheptano y ciclooctano sustituidos y su uso.
WO1994005732A3 (en)	1994-07-21	Carbon blacks
IL150329A0 (en)	2002-12-01	2-(1h-indol-3-yl)-2-oxo-acetamides with antitumor activity
RU95112463A (ru)	1997-03-20	Способ получения содержащих лигнин полимеров, лигнин-содержащие полимеры
AU3307100A (en)	2000-10-09	Crosslinkable coating compositions
EE200100287A (et)	2002-10-15	Puidukaitsevahendite lahused
AU6832498A (en)	1998-11-13	Substituted benzyl oximino compounds
DE60003560D1 (de)	2003-07-31	1,2-dihydro-1-oxo-pyrazino[1,2-]indolederivate
AU7655600A (en)	2001-04-30	1,4-dioxacycloalkane-2-one and 1,4-dioxacycloalkene-2-one
AU2002222218A1 (en)	2002-06-24	Cyclophilin-binding ligands